Biotech Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) announced on Tuesday the identification of several monoclonal antibody drug candidates that selectively target toxic forms of the protein alpha-synuclein, which is considered to be a root cause of Parkinson's disease.
To find out more on this announcement, click here.
After two unsuccessful late-stage clinical trials of crenezumab, which might have offered a disease-modifying therapy for Alzheimer's disease, ProMIS recently statedthat the phase three failure of crenezumab put pressure the urgent need for drug candidates that are highly selective for the toxic oligomer of amyloid beta.
FULL DISCLOSURE: ProMIS Neurosciences Inc. is a client of Stockhouse Publishing.